Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Pepijn Eijsvogel(Leiden University), Jean‐Cosme Dodart, Igor Radanović(Leiden University), Geert Jan Groeneveld(Centre for Human Drug Research), Marieke L. de Kam(Centre for Human Drug Research), Lauren Fedor, Philip H. C. Kremer(Leiden University), Hui Jing Yu, Luis Concha‐Marambio(Amprion (United States)), Shuang Ding(Chinese Academy of Sciences), Yihua Ma(Amprion (United States)), Dario Mirski, Maurits F. J. M. Vissers(Leiden University), Mohammad Shahnawaz, Carly M. Farris(Amprion (United States)), Pinaki Misra(Mayo Clinic in Arizona), Wolfgang Singer(Mayo Clinic), Ghazal Shareghi, Yu Sun(Qilu Hospital of Shandong University), Justin D. Boyd(Pfizer (United States)), Yueh-Ting Hsieh, Madeline M. Vroom(Kennedy Space Center)
Cited by 38
Related Papers
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
Optimizing the Cell Painting assay for image-based profiling
|Nature Protocols|2023|156
JUMP Cell Painting dataset: morphological impact of 136,000 chemical and genetic perturbations
|bioRxiv (Cold Spring Harbor Laboratory)|2023|101
<scp>DNL</scp>104, a Centrally Penetrant <scp>RIPK</scp>1 Inhibitor, Inhibits <scp>RIP</scp>1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers
|Clinical Pharmacology & Therapeutics|2019|77
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
|DOAJ (DOAJ: Directory of Open Access Journals)|2022|76